Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04824092




Registration number
NCT04824092
Ethics application status
Date submitted
22/03/2021
Date registered
1/04/2021
Date last updated
9/08/2024

Titles & IDs
Public title
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Secondary ID [1] 0 0
MOR208C310
Universal Trial Number (UTN)
Trial acronym
frontMIND
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diffuse Large B-cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tafasitamab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Rituximab
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Vincristine
Treatment: Drugs - Prednisone
Treatment: Drugs - Tafasitamab placebo
Treatment: Drugs - Lenalidomide placebo

Experimental: Tafasitamab plus lenalidomide in addition to R-CHOP - Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:

Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.

Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle

R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle

Placebo comparator: Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP - Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:

Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle

Lenalidomide placebo: Days 1-10 of each 21-day cycle

R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle


Treatment: Drugs: Tafasitamab
Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Lenalidomide
Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Rituximab
Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Doxorubicin
Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Vincristine
Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Prednisone
Prednisone PO will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Tafasitamab placebo
0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.

Treatment: Drugs: Lenalidomide placebo
Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PFS-INV
Timepoint [1] 0 0
Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)
Secondary outcome [1] 0 0
EFS-INV
Timepoint [1] 0 0
From randomization until the first occurrence of disease progression or relapse as assessed by the INV using, start of new anti-lymphoma treatment or death from any cause, whichever occurs first (up to 43 months)
Secondary outcome [2] 0 0
OS
Timepoint [2] 0 0
From randomization until the date of death from any cause (up to 62 months)
Secondary outcome [3] 0 0
Metabolic PET-negative CR-rate at EOT by BIRC
Timepoint [3] 0 0
End of treatment, 4-8 weeks after last dose
Secondary outcome [4] 0 0
Metabolic PET-negative CR-rate at EOT by INV
Timepoint [4] 0 0
End of treatment, 4-8 weeks after last dose
Secondary outcome [5] 0 0
ORR as per INV at EOT
Timepoint [5] 0 0
6 ± 2 weeks after End of Treatment
Secondary outcome [6] 0 0
Time to next anti-lymphoma treatment (TTNT)
Timepoint [6] 0 0
From randomization date to start of next anti-lymphoma therapy (for any reason including disease progression, treatment toxicity, and patient preference) or death due to any cause, whatever comes first (up to 43 months)
Secondary outcome [7] 0 0
Duration of Complete Response (CR) as assessed by the investigator
Timepoint [7] 0 0
From the date of the first occurrence of a documented CR, to the date of progression, relapse, or death from any cause, whichever is earlier (up to 43 months)
Secondary outcome [8] 0 0
EFS at 3 years
Timepoint [8] 0 0
36 months after randomization
Secondary outcome [9] 0 0
PFS at 3 years
Timepoint [9] 0 0
36 months after randomization
Secondary outcome [10] 0 0
OS at 3 years
Timepoint [10] 0 0
36 months after randomization

Eligibility
Key inclusion criteria
Major

* Previously untreated patients with local biopsy-proven, CD20-positive DLBCL, including one of the following diagnoses by 2016 World Health Organization (WHO) classification of lymphoid neoplasms are eligible:

1. DLBCL, NOS including GCB type, ABC type
2. T-cell rich large BCL
3. Epstein-Barr virus-positive DLBCL, NOS
4. Anaplastic lymphoma kinase (ALK)-positive large BCL
5. Human herpes virus-8 (HHV8)-positive DLBCL, NOS
6. High-grade BCL with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma). Please note: Patients must be appropriate candidates for R-CHOP. If an investigator deems a patient with a known double- or triple-hit lymphoma (HGBL) should be treated more aggressively (e.g. dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab [DA-EPOCH-R] or cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) followed by methotrexate and cytarabine [Hyper CVAD]), this patient would not be considered eligible for this study
7. HGBL-NOS
8. DLBCL coexistent with either follicular lymphoma (FL) of any grade, gastric MALT lymphoma or non-gastric MALT lymphoma
9. FL grade 3b
* Availability of archival or freshly collected tumor tissue sent for retrospective central pathology review
* IPI status of 3 to 5 (for patients > 60 years of age) or aaIPI 2 to 3 (for patients = 60 years of age)
* Diagnosis to treatment interval, defined as the time between the date of DLBCL diagnosis (date of the first biopsy specimen containing B Cell lymphoma according to the local pathology report) and the start of treatment (C1D1) = 28 days
* ECOG performance status of 0, 1, or 2
* Left ventricular ejection fraction equal to or greater 50% as assessed by local echocardiography or cardiac multi-gated acquisition (MUGA) scan
* Adequate hematologic function
* Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from breast feeding and donating eggs; agreement to ongoing pregnancy testing during the course of the study, and after study therapy has ended
* Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm

Major
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any other histological type of lymphoma according to WHO 2016 classification of lymphoid neoplasms, e.g., primary mediastinal (thymic) large B-cell lymphoma, Burkitt's lymphoma, BCL, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma); primary effusion lymphoma; primary cutaneous DLBCL, leg type; primary DLBCL of the CNS; DLBCL arising from CLL or indolent lymphoma
* History of prior non-hematologic malignancy except for the following:

1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening
2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer
3. Adequately treated carcinoma in situ without current evidence of disease
* Any systemic anti-lymphoma and/or investigational therapy prior to the start of C1D1, except for permitted pre-phase treatment
* Contraindication to any of the individual components of R-CHOP, including prior receipt of anthracyclines
* Known CNS lymphoma involvement
* Known active systemic bacterial, viral, fungal, or other infection at screening, including patients with suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay)
* History or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that in the investigator's opinion would preclude participation in the study or compromise the patient's ability to give informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/05/2026
Actual
Sample size
Target
Accrual to date
Final
899
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
MorphoSys Research Site - Adelaide
Recruitment hospital [2] 0 0
MorphoSys Research Site - Ballarat
Recruitment hospital [3] 0 0
MorphoSys Research Site - Birtinya
Recruitment hospital [4] 0 0
MorphoSys Research Site - Brisbane
Recruitment hospital [5] 0 0
MorphoSys Research Site - Canberra
Recruitment hospital [6] 0 0
MorphoSys Research Site - Clayton
Recruitment hospital [7] 0 0
MorphoSys Research Site - Frankston
Recruitment hospital [8] 0 0
MorphoSys Research Site - Geelong
Recruitment hospital [9] 0 0
MorphoSys Research Site - Gold Coast
Recruitment hospital [10] 0 0
MorphoSys Research Site - Gosford
Recruitment hospital [11] 0 0
MorphoSys Research Site - Greenslopes
Recruitment hospital [12] 0 0
MorphoSys Research Site - Hobart
Recruitment hospital [13] 0 0
MorphoSys Research Site - Kingswood
Recruitment hospital [14] 0 0
MorphoSys Research Site - Kogarah
Recruitment hospital [15] 0 0
MorphoSys Research Site - Launceston
Recruitment hospital [16] 0 0
MorphoSys Research Site - Malvern
Recruitment hospital [17] 0 0
MorphoSys Research Site - Melbourne
Recruitment hospital [18] 0 0
MorphoSys Research Site - Nedlands
Recruitment hospital [19] 0 0
MorphoSys Research Site - Perth
Recruitment hospital [20] 0 0
MorphoSys Research Site - Richmond
Recruitment hospital [21] 0 0
MorphoSys Research Site - St. Albans
Recruitment hospital [22] 0 0
MorphoSys Research Site - Sydney
Recruitment hospital [23] 0 0
MorphoSys Research Site - Townsville
Recruitment hospital [24] 0 0
MorphoSys Research Site - Wahroonga
Recruitment hospital [25] 0 0
MorphoSys Research Site - Waratah
Recruitment hospital [26] 0 0
MorphoSys Research Site - Wollongong
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3353 - Ballarat
Recruitment postcode(s) [3] 0 0
4575 - Birtinya
Recruitment postcode(s) [4] 0 0
4101 - Brisbane
Recruitment postcode(s) [5] 0 0
2605 - Canberra
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
VIC 3199 - Frankston
Recruitment postcode(s) [8] 0 0
3220 - Geelong
Recruitment postcode(s) [9] 0 0
QLD 4217 - Gold Coast
Recruitment postcode(s) [10] 0 0
2250 - Gosford
Recruitment postcode(s) [11] 0 0
4120 - Greenslopes
Recruitment postcode(s) [12] 0 0
7000 - Hobart
Recruitment postcode(s) [13] 0 0
2747 - Kingswood
Recruitment postcode(s) [14] 0 0
2217 - Kogarah
Recruitment postcode(s) [15] 0 0
TAS 7250 - Launceston
Recruitment postcode(s) [16] 0 0
3144 - Malvern
Recruitment postcode(s) [17] 0 0
3065 - Melbourne
Recruitment postcode(s) [18] 0 0
3084 - Melbourne
Recruitment postcode(s) [19] 0 0
6009 - Nedlands
Recruitment postcode(s) [20] 0 0
6000 - Perth
Recruitment postcode(s) [21] 0 0
6150 - Perth
Recruitment postcode(s) [22] 0 0
3121 - Richmond
Recruitment postcode(s) [23] 0 0
3021 - St. Albans
Recruitment postcode(s) [24] 0 0
2050 - Sydney
Recruitment postcode(s) [25] 0 0
2145 - Sydney
Recruitment postcode(s) [26] 0 0
4817 - Townsville
Recruitment postcode(s) [27] 0 0
8833 - Wahroonga
Recruitment postcode(s) [28] 0 0
2298 - Waratah
Recruitment postcode(s) [29] 0 0
2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Hawaii
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Cipolletti
Country [26] 0 0
Argentina
State/province [26] 0 0
Rosario
Country [27] 0 0
Argentina
State/province [27] 0 0
San Miguel de Tucuman
Country [28] 0 0
Austria
State/province [28] 0 0
Innsbruck
Country [29] 0 0
Austria
State/province [29] 0 0
Linz
Country [30] 0 0
Austria
State/province [30] 0 0
Rankweil
Country [31] 0 0
Austria
State/province [31] 0 0
St. Poelten
Country [32] 0 0
Austria
State/province [32] 0 0
Vienna
Country [33] 0 0
Canada
State/province [33] 0 0
Halifax
Country [34] 0 0
Canada
State/province [34] 0 0
London
Country [35] 0 0
Canada
State/province [35] 0 0
Montreal
Country [36] 0 0
Canada
State/province [36] 0 0
Saskatoon
Country [37] 0 0
Canada
State/province [37] 0 0
Sherbrooke
Country [38] 0 0
Colombia
State/province [38] 0 0
Medellin
Country [39] 0 0
Colombia
State/province [39] 0 0
Valledupar
Country [40] 0 0
Czechia
State/province [40] 0 0
Brno
Country [41] 0 0
Czechia
State/province [41] 0 0
Hradec Králové
Country [42] 0 0
Czechia
State/province [42] 0 0
Olomouc
Country [43] 0 0
Czechia
State/province [43] 0 0
Ostrava
Country [44] 0 0
Czechia
State/province [44] 0 0
Prague
Country [45] 0 0
France
State/province [45] 0 0
Cedex 9
Country [46] 0 0
France
State/province [46] 0 0
Pessac Cedax
Country [47] 0 0
France
State/province [47] 0 0
Amiens
Country [48] 0 0
France
State/province [48] 0 0
Bordeaux
Country [49] 0 0
France
State/province [49] 0 0
La Tronche
Country [50] 0 0
France
State/province [50] 0 0
Le Chesnay
Country [51] 0 0
France
State/province [51] 0 0
Le Mans
Country [52] 0 0
France
State/province [52] 0 0
Lille
Country [53] 0 0
France
State/province [53] 0 0
Limoges
Country [54] 0 0
France
State/province [54] 0 0
Marseille
Country [55] 0 0
France
State/province [55] 0 0
Nantes
Country [56] 0 0
France
State/province [56] 0 0
Poitiers
Country [57] 0 0
France
State/province [57] 0 0
Quimper
Country [58] 0 0
France
State/province [58] 0 0
Saint-Priest-en-Jarez
Country [59] 0 0
France
State/province [59] 0 0
Vandoeuvre-lès-Nancy
Country [60] 0 0
France
State/province [60] 0 0
Vannes
Country [61] 0 0
Germany
State/province [61] 0 0
Aachen
Country [62] 0 0
Germany
State/province [62] 0 0
Augsburg
Country [63] 0 0
Germany
State/province [63] 0 0
Berlin
Country [64] 0 0
Germany
State/province [64] 0 0
Bonn
Country [65] 0 0
Germany
State/province [65] 0 0
Chemnitz
Country [66] 0 0
Germany
State/province [66] 0 0
Cottbus
Country [67] 0 0
Germany
State/province [67] 0 0
Göttingen
Country [68] 0 0
Germany
State/province [68] 0 0
Halle
Country [69] 0 0
Germany
State/province [69] 0 0
Heilbronn
Country [70] 0 0
Germany
State/province [70] 0 0
Jena
Country [71] 0 0
Germany
State/province [71] 0 0
Kassel
Country [72] 0 0
Germany
State/province [72] 0 0
Luebeck
Country [73] 0 0
Germany
State/province [73] 0 0
Magdeburg
Country [74] 0 0
Germany
State/province [74] 0 0
Mainz
Country [75] 0 0
Germany
State/province [75] 0 0
Marburg
Country [76] 0 0
Germany
State/province [76] 0 0
Muenster
Country [77] 0 0
Germany
State/province [77] 0 0
Munich
Country [78] 0 0
Germany
State/province [78] 0 0
Paderborn
Country [79] 0 0
Germany
State/province [79] 0 0
Tuebingen
Country [80] 0 0
Germany
State/province [80] 0 0
Wiesbaden
Country [81] 0 0
Germany
State/province [81] 0 0
Wuerzburg
Country [82] 0 0
Germany
State/province [82] 0 0
Wuppertal
Country [83] 0 0
Hungary
State/province [83] 0 0
Budapest
Country [84] 0 0
Hungary
State/province [84] 0 0
Debrecen
Country [85] 0 0
Hungary
State/province [85] 0 0
Gyor
Country [86] 0 0
Hungary
State/province [86] 0 0
Nyíregyháza
Country [87] 0 0
Hungary
State/province [87] 0 0
Pécs
Country [88] 0 0
Ireland
State/province [88] 0 0
Dublin
Country [89] 0 0
Ireland
State/province [89] 0 0
Limerick
Country [90] 0 0
Israel
State/province [90] 0 0
Be'er Sheva
Country [91] 0 0
Israel
State/province [91] 0 0
Haifa
Country [92] 0 0
Israel
State/province [92] 0 0
Jerusalem
Country [93] 0 0
Israel
State/province [93] 0 0
Petah-Tikva
Country [94] 0 0
Israel
State/province [94] 0 0
Ramat Gan
Country [95] 0 0
Israel
State/province [95] 0 0
Tel-Aviv
Country [96] 0 0
Italy
State/province [96] 0 0
Bergamo
Country [97] 0 0
Italy
State/province [97] 0 0
Brescia
Country [98] 0 0
Italy
State/province [98] 0 0
Candiolo
Country [99] 0 0
Italy
State/province [99] 0 0
Catania
Country [100] 0 0
Italy
State/province [100] 0 0
Forli
Country [101] 0 0
Italy
State/province [101] 0 0
Genoa
Country [102] 0 0
Italy
State/province [102] 0 0
Lecce
Country [103] 0 0
Italy
State/province [103] 0 0
Milan
Country [104] 0 0
Italy
State/province [104] 0 0
Novara
Country [105] 0 0
Italy
State/province [105] 0 0
Orbassano
Country [106] 0 0
Italy
State/province [106] 0 0
Padova
Country [107] 0 0
Italy
State/province [107] 0 0
Palermo
Country [108] 0 0
Italy
State/province [108] 0 0
Pavia
Country [109] 0 0
Italy
State/province [109] 0 0
Ravenna
Country [110] 0 0
Italy
State/province [110] 0 0
Rimini
Country [111] 0 0
Italy
State/province [111] 0 0
Rozzano
Country [112] 0 0
Italy
State/province [112] 0 0
Siena
Country [113] 0 0
Italy
State/province [113] 0 0
Terni
Country [114] 0 0
Italy
State/province [114] 0 0
Tricase
Country [115] 0 0
Italy
State/province [115] 0 0
Trieste
Country [116] 0 0
Italy
State/province [116] 0 0
Turin
Country [117] 0 0
Japan
State/province [117] 0 0
Fukuoka
Country [118] 0 0
Japan
State/province [118] 0 0
Gifu
Country [119] 0 0
Japan
State/province [119] 0 0
Ibaraki
Country [120] 0 0
Japan
State/province [120] 0 0
Isehara
Country [121] 0 0
Japan
State/province [121] 0 0
Kagoshima
Country [122] 0 0
Japan
State/province [122] 0 0
Nagoya
Country [123] 0 0
Japan
State/province [123] 0 0
Narita-shi
Country [124] 0 0
Japan
State/province [124] 0 0
Okayama
Country [125] 0 0
Japan
State/province [125] 0 0
Osakasayama-shi
Country [126] 0 0
Japan
State/province [126] 0 0
Osaka
Country [127] 0 0
Japan
State/province [127] 0 0
Sapporo
Country [128] 0 0
Japan
State/province [128] 0 0
Tachikawa
Country [129] 0 0
Japan
State/province [129] 0 0
Tokyo
Country [130] 0 0
Japan
State/province [130] 0 0
Tsu-shi
Country [131] 0 0
Korea, Republic of
State/province [131] 0 0
Busan
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Daegu
Country [133] 0 0
Korea, Republic of
State/province [133] 0 0
Goyang-si
Country [134] 0 0
Korea, Republic of
State/province [134] 0 0
Incheon
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Jeonju
Country [136] 0 0
Korea, Republic of
State/province [136] 0 0
Jinju-si
Country [137] 0 0
Korea, Republic of
State/province [137] 0 0
Seoul
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Yangsan
Country [139] 0 0
Malaysia
State/province [139] 0 0
Alor Setar
Country [140] 0 0
Malaysia
State/province [140] 0 0
Ampang
Country [141] 0 0
Malaysia
State/province [141] 0 0
George Town
Country [142] 0 0
Malaysia
State/province [142] 0 0
Ipoh
Country [143] 0 0
Malaysia
State/province [143] 0 0
Johor Bahru
Country [144] 0 0
Malaysia
State/province [144] 0 0
Kota Bharu
Country [145] 0 0
Malaysia
State/province [145] 0 0
Kuala Lumpur
Country [146] 0 0
Malaysia
State/province [146] 0 0
Kuantan
Country [147] 0 0
Malaysia
State/province [147] 0 0
Kuching
Country [148] 0 0
Malaysia
State/province [148] 0 0
Petaling Jaya
Country [149] 0 0
Malaysia
State/province [149] 0 0
Subang Jaya
Country [150] 0 0
New Zealand
State/province [150] 0 0
Auckland
Country [151] 0 0
Philippines
State/province [151] 0 0
Manila
Country [152] 0 0
Philippines
State/province [152] 0 0
Pasig City
Country [153] 0 0
Philippines
State/province [153] 0 0
Quezon City
Country [154] 0 0
Poland
State/province [154] 0 0
Warsaw
Country [155] 0 0
Poland
State/province [155] 0 0
Lódz
Country [156] 0 0
Romania
State/province [156] 0 0
Brasov
Country [157] 0 0
Romania
State/province [157] 0 0
Bucharest
Country [158] 0 0
Romania
State/province [158] 0 0
Cluj-Napoca
Country [159] 0 0
Romania
State/province [159] 0 0
Craiova
Country [160] 0 0
Romania
State/province [160] 0 0
Iasi
Country [161] 0 0
Russian Federation
State/province [161] 0 0
Kazan
Country [162] 0 0
Russian Federation
State/province [162] 0 0
Moscow
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Novosibirsk
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Petrozavodsk
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Saint Petersburg
Country [166] 0 0
Russian Federation
State/province [166] 0 0
UFA
Country [167] 0 0
Serbia
State/province [167] 0 0
Belgrade
Country [168] 0 0
Serbia
State/province [168] 0 0
Novi Sad
Country [169] 0 0
Serbia
State/province [169] 0 0
Sremska Kamenica
Country [170] 0 0
Slovakia
State/province [170] 0 0
Bratislava
Country [171] 0 0
Slovakia
State/province [171] 0 0
Košice
Country [172] 0 0
Spain
State/province [172] 0 0
Badalona
Country [173] 0 0
Spain
State/province [173] 0 0
Barcelona
Country [174] 0 0
Spain
State/province [174] 0 0
Girona
Country [175] 0 0
Spain
State/province [175] 0 0
Jerez de la Frontera
Country [176] 0 0
Spain
State/province [176] 0 0
Lugo
Country [177] 0 0
Spain
State/province [177] 0 0
Madrid
Country [178] 0 0
Spain
State/province [178] 0 0
Pamplona
Country [179] 0 0
Spain
State/province [179] 0 0
Salamanca
Country [180] 0 0
Spain
State/province [180] 0 0
Seville
Country [181] 0 0
Spain
State/province [181] 0 0
Valencia
Country [182] 0 0
Spain
State/province [182] 0 0
Vitoria-Gasteiz
Country [183] 0 0
Taiwan
State/province [183] 0 0
Chang Hua
Country [184] 0 0
Taiwan
State/province [184] 0 0
Chiayi City
Country [185] 0 0
Taiwan
State/province [185] 0 0
Hualien City
Country [186] 0 0
Taiwan
State/province [186] 0 0
Kaohsiung
Country [187] 0 0
Taiwan
State/province [187] 0 0
New Taipei City
Country [188] 0 0
Taiwan
State/province [188] 0 0
Taichung
Country [189] 0 0
Taiwan
State/province [189] 0 0
Tainan
Country [190] 0 0
Taiwan
State/province [190] 0 0
Taipei
Country [191] 0 0
Taiwan
State/province [191] 0 0
Taoyuan
Country [192] 0 0
Thailand
State/province [192] 0 0
Bangkok
Country [193] 0 0
Thailand
State/province [193] 0 0
Chiang Mai
Country [194] 0 0
Thailand
State/province [194] 0 0
Khon Kaen
Country [195] 0 0
Thailand
State/province [195] 0 0
Pathum Thani
Country [196] 0 0
Turkey
State/province [196] 0 0
Ankara
Country [197] 0 0
Turkey
State/province [197] 0 0
Izmir
Country [198] 0 0
Turkey
State/province [198] 0 0
Izmit
Country [199] 0 0
Turkey
State/province [199] 0 0
Malatya
Country [200] 0 0
Turkey
State/province [200] 0 0
Mersin
Country [201] 0 0
Ukraine
State/province [201] 0 0
Cherkasy
Country [202] 0 0
Ukraine
State/province [202] 0 0
Chernihiv
Country [203] 0 0
Ukraine
State/province [203] 0 0
Kharkiv
Country [204] 0 0
Ukraine
State/province [204] 0 0
Kyiv
Country [205] 0 0
United Kingdom
State/province [205] 0 0
Aberdeen
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Bath
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Birmingham
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Bristol
Country [209] 0 0
United Kingdom
State/province [209] 0 0
London
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Nottingham
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Sutton
Country [212] 0 0
United Kingdom
State/province [212] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Incyte Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Trial website
https://clinicaltrials.gov/study/NCT04824092
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Incyte Medical Director
Address 0 0
Incyte Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04824092